Conference Presentation

Acumen's AAIC poster is patient survey data, not ALTITUDE-AD topline results

The July 14 presentation covers patient perspectives from the trial population, while the actual iADRS readout for sabirnetug is not due until the trial's October 2026 primary completion.

By AppliedXLJuly 14, 2026Trial NCT06335173

Executive Summary

Acumen is presenting a substudy on how patients and caregivers experience early Alzheimer's disease, drawn from the same trial population enrolled in its Phase 2 sabirnetug study, not a clinical efficacy result.
The presentation does not disclose the trial's primary cognitive endpoint result, and the trial itself remains active and has not reached its primary completion date.
The underlying trial is fully enrolled and stable, with no enrollment or timeline disruption behind this presentation.
Sabirnetug targets soluble amyloid oligomers rather than the plaque-focused mechanism used by the antibodies already approved or in late-stage testing for early Alzheimer's disease, positioning its readout as a test of a related but distinct hypothesis within the same target family.

The presentation

Acumen Pharmaceuticals is delivering one oral and two poster presentations at AAIC 2026 in London, running July 12 through July 15. The poster relevant to its lead Alzheimer's program, titled "Understanding Early Symptomatic Alzheimer's Disease Through Patient Perspectives: Findings from the ALTITUDE-AD Trial Population," is scheduled for July 14 and reports patient and caregiver perspectives collected from the ALTITUDE-AD study population, not the trial's cognitive endpoint data. Acumen's chief medical officer, Eric Siemers, said the AAIC data include "patient-perspective research from ALTITUDE-AD that may help inform the development of future treatment approaches for early Alzheimer's disease". The remaining two presentations cover preclinical brain-delivery work from Acumen's collaboration with JCR Pharmaceuticals and carry no bearing on sabirnetug's own clinical readout. Acumen

Probability of Success

Endpoint Met95%

Completes89%

Clinical Significance56%

Regulatory86%

The trial behind it

ALTITUDE-AD (NCT06335173) is a randomized, placebo-controlled Phase 2 study testing intravenous sabirnetug against placebo in 542 adults with mild cognitive impairment or mild dementia due to Alzheimer's disease, confirmed by amyloid PET or CSF testing. The trial's primary endpoint is change from baseline in the Integrated Alzheimer's Disease Rating Scale (iADRS) score, a composite of cognitive and functional decline. The study is Active, not recruiting, with a primary completion date of October 1, 2026, and no results have posted to ClinicalTrials.gov. Enrollment sits at 542, unchanged from the prior registry update, which the trial's own operational threshold classifies as a routine, non-material change. NCT06335173

Registry history

The trial's enrollment target was revised from 2,040 to 540 and its primary completion date moved from January 2031 to October 2026 in an October 2024 registry update, alongside a shift from Recruiting to Active, not recruiting status in December 2024. Those changes predate the current enrollment window and reflect an earlier redesign of the study rather than a recent disruption; enrollment has held stable at 542 since October 2025. NCT06335173

The competitive frame

Sabirnetug is designed to bind soluble amyloid-beta oligomers selectively, a distinct target within the amyloid-beta family from the plaque-clearing mechanism used by lecanemab and donanemab, both of which are active or approved in early Alzheimer's disease and share the same monoclonal antibody modality. Eli Lilly's remternetug, targeting amyloid-beta directly, is also in Phase 2/3 testing in the same population. None of these direct comparators share sabirnetug's oligomer-selective binding profile, which the sponsor has positioned as a mechanistic hypothesis for reducing the neurotoxic species implicated early in disease progression, distinct from clearing established plaque. Sabirnetug carries FDA Fast Track designation for early Alzheimer's disease, first granted in July 2024, which speeds the pace of FDA interaction but does not itself signal efficacy. Acumen

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.